U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H14N8O4S3
Molecular Weight 454.507
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFAZOLIN

SMILES

[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN4C=NN=N4)C(O)=O

InChI

InChIKey=MLYYVTUWGNIJIB-BXKDBHETSA-N
InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1

HIDE SMILES / InChI

Molecular Formula C14H14N8O4S3
Molecular Weight 454.507
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, cefazolin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. Cefazolin is used to treat bacterial infections of the skin, moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. This drug also can be used for perioperative prophylaxis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ANCEF

Approved Use

Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1973
Curative
ANCEF

Approved Use

Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1973
Curative
ANCEF

Approved Use

Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1973
Curative
ANCEF

Approved Use

Cefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1973
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
280.9 μg/mL
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFAZOLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
509.9 μg × h/mL
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFAZOLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.01 h
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFAZOLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4 g 2 times / day multiple, intravenous
Studied dose
Dose: 4 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 2 times / day
Sources:
healthy, 21 to 35 years
n = 7
Health Status: healthy
Age Group: 21 to 35 years
Sex: M
Population Size: 7
Sources:
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (14.3%)
Sources:
1.5 g 8 times / day multiple, intravenous
Highest studied dose
Dose: 1.5 g, 8 times / day
Route: intravenous
Route: multiple
Dose: 1.5 g, 8 times / day
Sources:
unhealthy, 21-34 years
n = 4
Health Status: unhealthy
Condition: endocarditis
Age Group: 21-34 years
Sex: M+F
Population Size: 4
Sources:
1 g 4 times / day multiple, intravenous
Recommended
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
healthy, 75 years
n = 1
Health Status: healthy
Age Group: 75 years
Sex: F
Population Size: 1
Sources:
Other AEs: Pseudomembranous colitis...
Other AEs:
Pseudomembranous colitis
Sources:
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy
n = 75
Health Status: unhealthy
Condition: closed fractures
Population Size: 75
Sources:
Other AEs: Infection...
Other AEs:
Infection (serious, 15 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Rash 14.3%
Disc. AE
4 g 2 times / day multiple, intravenous
Studied dose
Dose: 4 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 2 times / day
Sources:
healthy, 21 to 35 years
n = 7
Health Status: healthy
Age Group: 21 to 35 years
Sex: M
Population Size: 7
Sources:
Pseudomembranous colitis
1 g 4 times / day multiple, intravenous
Recommended
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
healthy, 75 years
n = 1
Health Status: healthy
Age Group: 75 years
Sex: F
Population Size: 1
Sources:
Infection serious, 15 patients
1 g 3 times / day multiple, intravenous
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy
n = 75
Health Status: unhealthy
Condition: closed fractures
Population Size: 75
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Ki 1740 uM]
yes [Ki 180 uM]
yes [Ki 550 uM]
PubMed

PubMed

TitleDatePubMed
[Nephrotoxicity of cefodizime sodium in rats--single and 14-day repeated intravenous administration].
1988 Jun
Comparison of in vitro antimicrobial susceptibilities of Mycobacterium avium-M. intracellulare strains from patients with acquired immunodeficiency syndrome (AIDS), patients without AIDS, and animal sources.
1990 Jul
Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared with existing congeners.
1999 Nov 5
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Fine structural recognition specificities of IgE antibodies distinguishing amoxicilloyl and amoxicillanyl determinants in allergic subjects.
2001 Sep-Oct
Stability of cefazolin sodium in icodextrin-containing peritoneal dialysis solution.
2002 Dec 1
Differences in neutrophil death among beta-lactam antibiotics after in vitro killing of bacteria.
2002 Jul
Effect of water content on the solid-state stability in two isomorphic clathrates of cephalosporin: cefazolin sodium pentahydrate (alpha form) and FK041 hydrate.
2002 Jun
Stability of three cephalosporin antibiotics in AutoDose Infusion System bags.
2002 May-Jun
The effect of additives on the crystallization of cefazolin sodium during freeze-drying.
2003 Feb
The effects of some antibiotics on sheep lens glucose 6-phosphate dehydrogenase in vitro.
2003 Mar
The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
2004 Apr
Antibiotic activity and synergistic effect of antimicrobial peptide against pathogens from a patient with gallstones.
2004 Aug 27
In situ investigation of drug diffusion in hydrogels by the refractive index method.
2004 May 15
Efficacy of a non-vancomycin-based peritoneal dialysis peritonitis protocol.
2005 Apr
Effect of isoniazid on the pharmacodynamics of cefazolin-induced seizures in rats.
2005 Apr
Voltammetric behavior and assay of the antibiotic drug cefazolin sodium in bulk form and pharmaceutical formulation at a mercury electrode.
2005 Oct 4
Graft infectivity of rifampin and silver-bonded polyester grafts to MRSA contamination.
2005 Sep-Oct
Radiographic and computed tomographic evaluation of experimentally induced lung aspiration sites in dogs.
2006 Dec
Attenuation of ischemia-reperfusion injury by ascorbic acid in the canine renal transplantation.
2006 Dec
Infective endocarditis with an aortic periannular abscess extending along the right coronary artery.
2006 Jun
Conventional and dense gas techniques for the production of liposomes: a review.
2008
Cefazolin-induced hypoprothrombinemia.
2008 May 1
[Retropharyngeal abscesses: a retrospective analysis of 10 patients].
2008 Sep-Oct
Functional recovery and neural differentiation after transplantation of allogenic adipose-derived stem cells in a canine model of acute spinal cord injury.
2009 Dec
The effects of methylprednisolone and cefazolin sodium on antioxidant status in experimentally induced maxillary sinusitis.
2009 Oct
Evaluating intra- and inter-examiner reproducibility in histometric measurement: one-wall intrabony periodontal defects in beagle dogs.
2010 Aug
Osteoid osteoma of the femur in a 7-month-old infant treated with radiofrequency ablation.
2010 Nov
Investigation of the toxic functional group of cephalosporins by zebrafish embryo toxicity test.
2010 Oct
Patents

Sample Use Guides

Moderate to severe infections: 500 mg to 1 gram, every 6 to 8 hours; mild infections caused by susceptible gram-positive cocci: 250 mg to 500 mg, every 8 hours; acute, uncomplicated urinary tract infections: 1 gram, every 12 hours; Pneumococcal pneumonia: 500 mg, every 12 hours; Severe, life threatening infections (e.g., endocarditis, septicemia): 1 gram to 1.5 grams, every 6 hours
Route of Administration: Other
In Vitro Use Guide
Susceptibilities of 259 isolates of pathogenic bacteria to cefazolin were measured by broth and agar dilution procedures. Beta-hemolytic streptococci were inhibited by 0.25 mug/ml, whereas Staphylococcus aureus and alphahemolytic streptococci were inhibited by 2.0 mug/ml. Enterococci were resistant to less than 32 mug/ml. Wide variation was seen with gram-negative species. Most isolates of Klebsiella species and Proteus mirabilis were inhibited by 4.0 or 8.0 mug/ml. Escherichia coli were less susceptible, and most isolates of Pseudomonas aeruginosa, Serratia species, and Enterobacter species were resistant to 128 mug/ml.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:20:19 GMT 2023
Edited
by admin
on Fri Dec 15 15:20:19 GMT 2023
Record UNII
IHS69L0Y4T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFAZOLIN
HSDB   INN   MART.   MI   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
CEFAZOLIN [MI]
Common Name English
cefazolin [INN]
Common Name English
CEFAZOLIN [USP MONOGRAPH]
Common Name English
Cefazolin [WHO-DD]
Common Name English
(6R,7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Systematic Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 3-(((5-METHYL-1,3,4-THIADIAZOL-2-YL)THIO)METHYL)-8-OXO-7-(((1H-TETRAZOL-1-YL)ACETYL)AMINO)-(6R-TRANS)
Common Name English
J01DB04
Code English
CEFAZOLIN [VANDF]
Common Name English
CEFAZOLIN [HSDB]
Common Name English
CEFAZOLIN [MART.]
Common Name English
CEFAZOLIN [USP-RS]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
LIVERTOX NBK548358
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
LIVERTOX NBK547862
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.1
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
WHO-ATC J01DB04
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NCI_THESAURUS C357
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NDF-RT N0000175488
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
LIVERTOX NBK548666
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
WHO-VATC QJ51DB04
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
NDF-RT N0000011161
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
WHO-VATC QJ01DB04
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1097603
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
CHEBI
474053
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
DRUG CENTRAL
530
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
ChEMBL
CHEMBL1435
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
NCI_THESAURUS
C28913
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
WIKIPEDIA
CEFAZOLIN
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
PUBCHEM
33255
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
LACTMED
Cefazolin
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
RXCUI
2180
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY RxNorm
MESH
D002437
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
ECHA (EC/EINECS)
247-362-8
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
EPA CompTox
DTXSID2022753
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
CAS
25953-19-9
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
EVMPD
SUB07379MIG
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
DRUG BANK
DB01327
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
DAILYMED
IHS69L0Y4T
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
INN
2991
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
SMS_ID
100000081793
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
MERCK INDEX
m3188
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY Merck Index
HSDB
3213
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
FDA UNII
IHS69L0Y4T
Created by admin on Fri Dec 15 15:20:19 GMT 2023 , Edited by admin on Fri Dec 15 15:20:19 GMT 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
EXCRETED UNCHANGED
Cefazolin is excreted unchanged in the urine. In the first 6 hours approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours.
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC